ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
Clinical efficacy and risk factors of colistin sulfate in the treatment of carbapenem
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesInfections caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) have become a global public health concern because of their high incidence and mortality. Although intravenous colistin sulfate has been widely used for the treatment of CR-GNB infections, systematic evaluations of its clinical efficacy and safety remain limited. This study aims to evaluate the clinical efficacy and safety of colistin sulfate in the treatment of CR-GNB infections and to analyze factors associated with therapeutic efficacy and prognosis, thereby providing evidence for rational clinical use and improved patient outcomes.
methodsClinical data of patients from the Third Xiangya Hospital of Central South University who received intravenous colistin sulfate for CR-GNB infections between July 2020 and March 2023 were retrospectively collected, including demographic characteristics, infection-related information (infection sites, pathogens, and antimicrobial susceptibility results), concomitant medications (drug type, dosage, and treatment duration), laboratory findings, and patient outcomes. The clinical efficacy and safety of colistin sulfate for CR-GNB infections were evaluated, and the 30‑day all‑cause mortality and microbiological eradication rate were analyzed. Multivariable Logistic regression analysis was performed to identify independent risk factors affecting the clinical efficacy of colistin sulfate treatment and to construct a predictive model. The predictive performance of the model was assessed using the area under the receiver operating characteristic curve (AUROC). Kaplan‑Meier curves and Cox regression models were used to analyze factors associated with 30-day all-cause mortality.
resultsA total of 112 patients with CR-GNB infections were included. Among them, 85.7% were admitted to the intensive care unit (ICU), 67.9% received mechanical ventilation, and 51.8% required vasopressor support. The lung was the most common site of infection (81.3%), followed by bloodstream infection (17.0%). The predominant pathogens were
conclusionsColistin sulfate is effective in the treatment of CR-GNB infections. Treatment duration ≥7 d is an independent factor associated with improved clinical efficacy and survival. During adequate treatment courses, the emergence of colistin resistance should be closely monitored, and combination regimens should be selected according to antimicrobial susceptibility results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.